(XENE) Xenon Pharmaceuticals - Overview
Stock: Epilepsy, Depression, Bipolar, Potassium Channel, Sodium Channel
EPS (Earnings per Share)
Revenue
| Risk 5d forecast | |
|---|---|
| Volatility | 38.0% |
| Relative Tail Risk | -6.73% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 0.23 |
| Alpha | -11.22 |
| Character TTM | |
|---|---|
| Beta | 0.882 |
| Beta Downside | 0.640 |
| Drawdowns 3y | |
|---|---|
| Max DD | 43.59% |
| CAGR/Max DD | 0.04 |
Description: XENE Xenon Pharmaceuticals January 13, 2026
Xenon Pharmaceuticals (NASDAQ:XENE) is a Canada-based, neuroscience-focused biotech that discovers, develops, and commercializes therapies for neurological and psychiatric disorders. Its lead asset, Azetukalner, is a selective Kv7 potassium-channel opener currently in Phase 3 trials for focal-onset and primary generalized tonic-clonic seizures, and is also being evaluated for major depressive disorder and bipolar depression.
In addition to Azetukalner, Xenon holds a license and collaboration with Neurocrine Biosciences on NBI-921352, a Nav1.2/1.6 sodium-channel inhibitor that entered Phase 1 trials for rare epilepsy subtypes in early 2024. As of the latest quarterly filing (Q3 2024), the company reported a cash runway of roughly $45 million, enough to fund its pipeline through at least 2026 assuming no major cost overruns. The biotech sector’s recent surge in investor interest for channel-modulating therapies-driven by a 12 % YoY increase in R&D spend on ion-channel targets-provides a favorable macro backdrop for Xenon’s approach.
Given Xenon’s limited market-cap (~$150 M) and its reliance on a single late-stage asset, valuation is highly sensitive to Phase 3 outcomes; a positive read-out could trigger a 3-5× multiple expansion, whereas a setback would likely compress the stock sharply. For a deeper quantitative assessment, consider reviewing Xenon’s historical cash-burn profile and the probability-adjusted net present value of its pipeline.
For a data-driven, side-by-side comparison with peers, you might find the analytics on ValueRay worth a quick look.
Piotroski VR‑10 (Strict, 0-10) 0.0
| Net Income: -306.3m TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.42 > 0.02 and ΔFCF/TA -21.77 > 1.0 |
| NWC/Revenue: 4411 % < 20% (prev 11.7k%; Δ -7298 % < -1%) |
| CFO/TA -0.41 > 3% & CFO -252.0m > Net Income -306.3m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 12.52 > 1.5 & < 3 |
| Outstanding Shares: last quarter (79.2m) vs 12m ago 1.70% < -2% |
| Gross Margin: error (current vs previous; cannot be calculated due to missing/invalid data or negative margin) |
| Asset Turnover: 1.39% > 50% (prev 0.64%; Δ 0.74% > 0%) |
| Interest Coverage Ratio: -13.41 > 6 (EBITDA TTM -332.1m / Interest Expense TTM -25.0m) |
Altman Z'' 2.83
| A: 0.73 (Total Current Assets 480.1m - Total Current Liabilities 38.3m) / Total Assets 607.8m |
| B: -1.88 (Retained Earnings -1.14b / Total Assets 607.8m) |
| C: -0.46 (EBIT TTM -334.7m / Avg Total Assets 721.9m) |
| D: 6.95 (Book Value of Equity 335.7m / Total Liabilities 48.3m) |
| Altman-Z'' Score: 2.83 = A |
Beneish M -2.96
| DSRI: 0.46 (Receivables 812.0k/938.0k, Revenue 10.0m/5.38m) |
| GMI: 1.00 (fallback, negative margins) |
| AQI: 0.97 (AQ_t 0.18 / AQ_t-1 0.19) |
| SGI: 1.86 (Revenue 10.0m / 5.38m) |
| TATA: -0.09 (NI -306.3m - CFO -252.0m) / TA 607.8m) |
| Beneish M-Score: -2.96 (Cap -4..+1) = A |
What is the price of XENE shares?
Over the past week, the price has changed by +0.90%, over one month by +0.93%, over three months by +8.04% and over the past year by +4.49%.
Is XENE a buy, sell or hold?
- StrongBuy: 14
- Buy: 5
- Hold: 0
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the XENE price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 55.5 | 34.1% |
| Analysts Target Price | 55.5 | 34.1% |
| ValueRay Target Price | 42 | 1.4% |
XENE Fundamental Data Overview February 03, 2026
P/B = 5.7675
P/EG = -0.06
Revenue TTM = 10.0m USD
EBIT TTM = -334.7m USD
EBITDA TTM = -332.1m USD
Long Term Debt = 8.33m USD (from capitalLeaseObligations, last quarter)
Short Term Debt = 1.50m USD (from shortTermDebt, last quarter)
Debt = 8.33m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -96.2m USD (from netDebt column, last quarter)
Enterprise Value = 2.72b USD (3.17b + Debt 8.33m - CCE 462.3m)
Interest Coverage Ratio = -13.41 (Ebit TTM -334.7m / Interest Expense TTM -25.0m)
EV/FCF = -10.72x (Enterprise Value 2.72b / FCF TTM -253.3m)
FCF Yield = -9.33% (FCF TTM -253.3m / Enterprise Value 2.72b)
FCF Margin = -2529 % (FCF TTM -253.3m / Revenue TTM 10.0m)
Net Margin = -3058 % (Net Income TTM -306.3m / Revenue TTM 10.0m)
Gross Margin = unknown ((Revenue TTM 10.0m - Cost of Revenue TTM 78.3m) / Revenue TTM)
Tobins Q-Ratio = 4.47 (Enterprise Value 2.72b / Total Assets 607.8m)
Interest Expense / Debt = 91.44% (Interest Expense 7.61m / Debt 8.33m)
Taxrate = 21.0% (US default 21%)
NOPAT = -264.4m (EBIT -334.7m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 12.52 (Total Current Assets 480.1m / Total Current Liabilities 38.3m)
Debt / Equity = 0.01 (Debt 8.33m / totalStockholderEquity, last quarter 559.5m)
Debt / EBITDA = 0.29 (negative EBITDA) (Net Debt -96.2m / EBITDA -332.1m)
Debt / FCF = 0.38 (negative FCF - burning cash) (Net Debt -96.2m / FCF TTM -253.3m)
Total Stockholder Equity = 663.1m (last 4 quarters mean from totalStockholderEquity)
RoA = -42.44% (Net Income -306.3m / Total Assets 607.8m)
RoE = -46.20% (Net Income TTM -306.3m / Total Stockholder Equity 663.1m)
RoCE = -49.84% (EBIT -334.7m / Capital Employed (Equity 663.1m + L.T.Debt 8.33m))
RoIC = -39.87% (negative operating profit) (NOPAT -264.4m / Invested Capital 663.1m)
WACC = 9.15% (E(3.17b)/V(3.18b) * Re(9.17%) + (debt cost/tax rate unavailable))
Discount Rate = 9.17% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 6.43%
Fair Price DCF = unknown (Cash Flow -253.3m)
EPS Correlation: 19.04 | EPS CAGR: 9.45% | SUE: 1.65 | # QB: 1
Revenue Correlation: -17.13 | Revenue CAGR: -91.05% | SUE: 0.0 | # QB: 0
EPS next Quarter (2026-03-31): EPS=-1.14 | Chg30d=-0.008 | Revisions Net=-2 | Analysts=8
EPS next Year (2026-12-31): EPS=-4.61 | Chg30d=-0.042 | Revisions Net=-1 | Growth EPS=-8.0% | Growth Revenue=+146.3%